TNDMHIGH SIGNALFINANCIAL10-K

TNDM's operating losses substantially worsened while the company implemented a new multi-channel managed care strategy that introduces significant execution risk.

The company's operating performance deteriorated meaningfully despite revenue growth, driven by substantially higher R&D spending and increased SG&A expenses, suggesting significant operational challenges. The new pharmacy channel strategy represents a fundamental shift in business model that management explicitly warns could "materially and adversely impact" results if unsuccessful, creating substantial execution risk for investors.

Comparing 2026-02-19 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

TNDM showed mixed financial results with gross profit growing modestly to $546M, but this was more than offset by substantially higher operating expenses, leading to significantly deeper operating losses. The balance sheet weakened with stockholders' equity declining 41% to $155.2M, though cash position improved modestly to $90.6M. The overall picture suggests a company investing heavily in R&D and strategy changes while struggling to maintain profitability, resulting in deteriorating financial metrics despite top-line growth.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-88.9%
-$99.1M→-$187.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+44.8%
$63.6M→$92.1M

R&D investment increased 44.8% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+44.4%
$114.6M→$165.5M

Receivables surged 44.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Stockholders Equity
Balance Sheet
-41%
$263.1M→$155.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
+30.9%
$69.2M→$90.6M

Cash position surged 30.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
-14.7%
$724.5M→$618.1M

Current assets declined 14.7% — monitor working capital adequacy and short-term liquidity.

SG&A Expense
P&L
+14.2%
$389.8M→$445.0M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Inventory
Balance Sheet
-13.9%
$149.6M→$128.8M

Inventory reduced 13.9% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
+11.5%
$489.6M→$546.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-26
ADDED
As of February 16, 2026, there were 68,325,927 shares of the registrant s common stock outstanding.
We are implementing a multi-channel managed care strategy in the United States that impacts the pricing model for our pumps and our supplies sold through the pharmacy channel.
If our pharmacy channel strategy fails to achieve its intended outcome, our growth, business, results of operations, and financial condition could be materially and adversely impacted.
Our ability to maintain and grow our sales depends in part on retaining a high percentage of our customer base.
Our sales and marketing efforts depend on independent distributors who are free to market products that compete with our products.
Risks Related to Our International Operations Commercializing our products internationally may result in a variety of risks associated with international operations that could materially adversely affect our business.
Risks Related to Our Indebtedness Servicing Convertible Senior Notes due 2029 (the 2029 Notes) will require a significant amount of cash, and we may not have sufficient cash flow from our business to repay the 2029 Notes.
New products or modifications to our existing products may require new 510(k) clearances, PMAs, CE Marks or other certifications, or may require us to cease marketing or recall the modified products until clearances, certifications or approvals are obtained.
Overview Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management.
We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide.
REMOVED
As of February 21, 2025, there were 66,473,272 shares of the registrant s common stock outstanding.
2 Our ability to maintain and grow our revenue depends in part on retaining a high percentage of our customer base.
Our sales and marketing efforts in the United States are largely dependent on independent distributors who are free to market products that compete with our products.
Risks Related to Our International Operations Commercializing our products outside of the United States may result in a variety of risks associated with international operations that could materially adversely affect our business.
Risks Related to Our Indebtedness We have incurred a significant amount of indebtedness and the agreements governing such indebtedness subject us to required debt service payments, as well as financial and operational covenants, any of which may restrict our financial flexibility and affect our ability to operate our business.
Servicing our senior convertible notes (the Notes) will require a significant amount of cash, and we may not have sufficient cash flow from our business to repay the Notes.
Climate change or other extreme weather conditions and related regulations may have a long-term impact on our business.
New products or modifications to our existing products may require new 510(k) clearances, PMAs or certifications, or may require us to cease marketing or recall the modified products until clearances, certifications or approvals are obtained.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud, which could harm our business and result in a decline in the trading price of our common stock.
Overview Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones and healthcare providers.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →